What are the opening hours?

Monday 9:30am - 5:30pm Tuesday 9:30am - 5:30pm Wednesday 9:30am - 5:30pm Thursday 9:30am - 5:30pm Friday 9:30am - 5:30pm

Cancer Research & Treatment Fund, Inc.

Home
United States
New York, NY
Cancer Research & Treatment Fund, Inc.

The official page of Cancer Research & Treatment Fund. Please follow us to receive our latest news. In 2012, CR&T began funding the Richard T. Silver.

The Cancer Research and Treatment Fund (CR&T) is a driving force in cancer research and treatment. Founded in 1968, we are a not-for-profit fund that is committed to the belief that advances in blood cancer research lead to important breakthroughs, and a better understanding of the biology and treatment of all forms of cancer. In 2000, CR&T and the generosity of donors were instrumental in the establishment of the Center for the Study of Leukemia and Myeloproliferative Neoplasms at Weill Cornell Medical College, a leading institution for cancer research. More recently, we have been involved with the breakthrough discoveries of Gleevec and now the JAK2 enzyme cancer marker . Silver Myeloproliferative Neoplasm Center at Weil Cornell Medical College, the successor to the Center for the Study of Leukemia and Myelproliferative Neoplasms at Weill Cornel Medical College. The center was dedicated in a special ceremony on February 18, 2014, and will serve as a translational research and treatment center, engaging in cutting edge discoveries surrounding MPNs. CR&T played a pivotal role in establishing the Silver MPN Center. In addition to contributing a $3.7 million gift, the Center is named after CR&T’s founder, Dr. Richard T. Dr. Andrew Schaefer, former Chairman of the Department of Medicine at Weill Cornell Medical College, has been appointed as the Center’s Director. We have achieved these successes by aggressively pursuing biological, pharmacological and molecular solutions to understand cancer, and to design drugs and diagnostic tools based on new knowledge—providing critical resources for a multidisciplinary approach that offers the greatest promise against all forms of cancer. For more than three decades, CR&T has been a major source of financial support for researchers on the frontlines of clinical cancer research at Weill Medical College of Cornell University, located at New York-Presbyterian Hospital. We have also awarded grants for research at Johns Hopkins University Medical Center, MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center.

03/25/2026

Clinical trials are key to advancing care for people living with MPNs. At the Silver MPN Center, patients have access to innovative trials that help define tomorrow’s therapies. Participation helps science AND patient care.

03/24/2026

A gift to CR&T has the potential to truly change the lives of those battling MPN's. No gift is too small to make a change. https://www.crt.org/donate/

03/23/2026

Symptoms of MPNs can vary widely—everything from fatigue to itching or abdominal fullness. If something feels “off,” trust your instincts and talk to your care team. Education empowers action.

03/19/2026

Register today!

Ghaith Abu Zeinah will host a free webinar on Thursday, March 26, 2026 at 12PM.

Click the link below to register now 👇

https://healthtree.org/myeloproliferative-neoplasm/community/events/mar26-mpns-progression-dr-zeinah

03/17/2026

Being diagnosed with a Myeloproliferative Neoplasm (MPN) is not just a physical journey—it’s an emotional one too. From the moment you hear those words, you’re not just dealing with a health condition, but with the mental and emotional weight of what lies ahead. It’s completely normal to feel overwhelmed, sad, or even angry as you process this new reality. YOU ARE NOT ALONE!

If you or someone you know is going through this, let's continue the conversation—sharing our feelings and experiences can help us all feel a little less alone.

03/14/2026

2026 Global MPN Patient Unmet Needs Assessment is now open!

MPN Research Foundation invites individuals living with a myeloproliferative neoplasm (MPN) to participate in the 2026 Global MPN Patient Unmet Needs Assessment.

This global effort helps us better understand patient experiences, priorities, and unmet needs from around the world. Healthcare access, treatments, and support can vary widely, and global participation is essential to ensure all voices are represented.

Topics include:
• MPN diagnosis & monitoring
• Therapies & clinical trials
• Symptoms & related conditions
• Access to information & resources
• Emotional health & quality of life

Take the assessment here: https://www.tfaforms.com/5184100

Preview highlights from the 2024 assessment: https://mpnresearchfoundation.org/mpn-unmet-needs-assessment-preview/

Preliminary results will be shared in Summer 2026

Please share widely — especially with international communities — to help identify unmet needs worldwide. 🌐

03/12/2026

Myeloproliferative neoplasms (MPNs) are chronic blood disorders that affect how your body makes blood cells. They can involve red cells, white cells, or platelets—and understanding this is the first step on your care journey. 💛

03/11/2026

SAVE THE DATE!

Knowledge empowers patients. Each year, CR&T hosts an International Patient Symposium to connect patients and caregivers with leading researchers and medical professionals. Educational presentations are recorded and shared with the community—because informed patients are stronger patients. 💙

03/10/2026

Impact matters. CR&T directs more than 80% of every dollar donated toward research and education initiatives—maximizing donor impact and accelerating scientific discovery.

Transparency. Accountability. Progress.

03/05/2026

Research supported by CR&T was highlighted Weill Cornell Medicine! CR&T grantee Dr. Despina Siolas and her team are pioneering work on personalizing pancreatic cancer treatment through KRAS research, bringing us closer to more effective, targeted therapies for patients.

We are we so proud to support this vital research and encourage you read more about Dr. Siolas’s work 👏👏

02/20/2026

Big congratulations to Aleksei Martianov, PhD, postdoctoral fellow in the Bergmeier Lab at the University of North Carolina at Chapel Hill, on receiving the inaugural ASH Richard T. Silver, MD Abstract Achievement Award for Myeloproliferative Neoplasms! 🎉

Dr. Martianov delivered an oral presentation at the recent ASH Annual Meeting, highlighting his abstract:

“Platelet Priming in MPN Triggers Prothrombotic Intermediate Affinity State in αIIbβ3 Integrin.”

This prestigious recognition reflects the impact of his research in advancing our understanding of myeloproliferative neoplasms and thrombosis.

Read the abstract here:
https://doi.org/10.1182/blood-2025-415

Please join us in celebrating this outstanding achievement!

02/17/2026

Every discovery starts with support.

Your contribution helps CR&T fund critical research aimed at improving outcomes for blood cancer patients.
💙 Support the mission: https://www.crt.org/donate/

Address

500 E 77th Street, Ste 1001
New York, NY
10162

Opening Hours

Monday	9:30am - 5:30pm
Tuesday	9:30am - 5:30pm
Wednesday	9:30am - 5:30pm
Thursday	9:30am - 5:30pm
Friday	9:30am - 5:30pm

Website

http://www.crt.org/

Alerts

Be the first to know and let us send you an email when Cancer Research & Treatment Fund, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Cancer Research & Treatment Fund, Inc.:

Shortcuts

Featured

Dr. Paul Gregory, DDS
57 W 57th Street
Magnus Wellness
16 E 40th Street, Fl 4

Our Story

The Cancer Research and Treatment Fund (CR&T) is a driving force in cancer research and treatment. Founded in 1968, we are a not-for-profit fund that is committed to the belief that advances in blood cancer research lead to important breakthroughs, and a better understanding of the biology and treatment of all forms of cancer. In 2000, CR&T and the generosity of donors were instrumental in the establishment of the Center for the Study of Leukemia and Myeloproliferative Neoplasms at Weill Cornell Medical College, a leading institution for cancer research. More recently, we have been involved with the breakthrough discoveries of Gleevec and now the JAK2 enzyme cancer marker . In 2012, CR&T began funding the Richard T. Silver Myeloproliferative Neoplasm Center at Weil Cornell Medical College, the successor to the Center for the Study of Leukemia and Myelproliferative Neoplasms at Weill Cornell Medical College. The center was dedicated in a special ceremony on February 18, 2014, and serves as a translational research and treatment center, engaging in cutting edge discoveries surrounding MPNs. CR&T played a pivotal role in establishing the Silver MPN Center. In addition to contributing a $3.7 million gift, the Center is named after CR&T’s founder, Dr. Richard T. Silver. Dr. Andrew Schafer, former Chairman of the Department of Medicine at Weill Cornell Medical College, has been appointed as the Center’s Director. We have achieved these successes by aggressively pursuing biological, pharmacological and molecular solutions to understand cancer, and to design drugs and diagnostic tools based on new knowledge—providing critical resources for a multidisciplinary approach that offers the greatest promise against all forms of cancer. CR&T will mark its 50th Anniversary in 2018. For nearly 50 years, the organization has been a major source of financial support for researchers on the frontlines of clinical cancer research at Weill Medical College of Cornell University, located at New York-Presbyterian Hospital. We have also awarded grants for research at Johns Hopkins University Medical Center, MD Anderson Cancer Center, and Memorial Sloan-Kettering Cancer Center.